Top Markets
#1 Helium Helium +114.48%
#2 MowCat MowCat +88.56%
#3 Seeker Seeker +62.86%
#4 UnifAI Network UnifAI Network +35.32%
#5 TENDIES TENDIES +27.62%
#6 pipedog pipedog +23.28%
#7 Zylo Ecosystem Zylo Ecosystem +21.92%
#8 Pons Pons +21.85%
#9 Bounce Bounce +21.52%
#10 Tensor Tensor +21.02%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
GuiZhou SanLi Pharmaceutical Co.,Ltd GuiZhou SanLi Pharmaceutical Co.,Ltd

GuiZhou SanLi Pharmaceutical Co.,Ltd

603439
Rank in Stocks #11342
This pharmaceutical enterprise is dedicated to the comprehensive process of... This pharmaceutical enterprise is dedicated to the comprehensive process of developing, manufacturing, and distributing medicinal products. Its diverse portfolio includes therapeutic solutions for children, respiratory ailments, cardiovascular and cerebrovascular disorders, digestive issues, trauma recovery, rehabilitation needs, and ophthalmic conditions. The company commenced operations in 1995 and maintains its primary base in Guiyang, China.
Share Price
$1.76
Last synced: 2026-08-28
Market Cap
$712.21M
Change (1 day)
-2.41%
Change (1 year)
-0.90%
Country
CN
Trade GuiZhou SanLi Pharmaceutical Co.,Ltd (603439)

Category

Healthcare
Revenue for GuiZhou SanLi Pharmaceutical Co.,Ltd (603439)
Revenue in Aug 2026 TTM: 0
According to GuiZhou SanLi Pharmaceutical Co.,Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for GuiZhou SanLi Pharmaceutical Co.,Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH